Monopar Therapeutics Inc. (MNPR) Cash Flow Statement
Where MNPR’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$12.2M
- Capital expenditures
- $0
- Free cash flow
- −$12.2M
- Returned to shareholders
- $35.0M
- Change in cash
- $16.0M cash at year-end $61.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
MNPR operating cash flow, capex and free cash flow
MNPR cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.2M2016 | −$12.2M2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$1.2M2016 | −$12.2M2025 | — | |
| Stock-based compensation | $305,2052017 | $4.8M2025 | +41.3%/yr | |
| Share buybacks (net) | $02016 | $35.0M2025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MNPR cash flow by activity
MNPR net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
MNPR cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$13.7M | −$15.6M | −$8.4M | −$10.5M | −$9.1M | −$6.3M | −$4.2M | −$3.2M | −$16.6M | −$1.2M |
| Depreciation & amortization | −$716.5M | — | — | — | — | $6.5M | — | $3.3M | $2.1M | $1.2M |
| Stock-based compensation | $4.8M | $1.1M | $1.9M | $1.6M | $1.5M | $1.3M | $1.0M | $529,332 | $305,205 | — |
| Change in working capital | −$2.6M | $3.5M | −$1.4M | $1.6M | $317,769 | $443,809 | $196,024 | −$188,157 | $120,577 | −$9,035 |
| Other non-cash items | $715.7M | $4.5M | $0 | $0 | $0 | −$6.6M | $0 | −$3.3M | $11.4M | −$1.2M |
| Cash from operating activities | −$12.2M | −$6.4M | −$7.9M | −$7.2M | −$7.3M | −$4.7M | −$3.0M | −$2.9M | −$2.6M | −$1.2M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$3 | $0 | −$1 | −$4 | $0 | $0 | $0 | $0 |
| Investments (net) | −$63.5M | −$14.3M | −$3.0M | −$4.9M | $0 | — | — | — | — | — |
| Acquisitions & other investing | $0 | $0 | $7.9M | $0 | — | — | — | — | — | — |
| Cash from investing activities | −$63.5M | −$14.3M | $4.9M | −$4.9M | — | — | — | — | — | — |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | −$35.0M | $0 | −$47 | −$77 | −$63 | $8.2M | $10.3M | — | $4.7M | $1.3M |
| Net borrowing (repayment) | — | — | — | — | $0 | $122,400 | $122,400 | $122,400 | $122,400 | — |
| Shares issued | $127.1M | $59.4M | $1.8M | $109,337 | $10.9M | $8.2M | $10.2M | $0 | $0 | $0 |
| Other financing | −$567,170 | −$104,136 | $183,611 | −$76,387 | −$45,712 | −$8.3M | −$11.3M | −$328,670 | $4.7M | $0 |
| Cash from financing activities | $91.6M | $59.3M | $2.0M | $32,873 | $10.9M | $8.2M | $9.3M | −$206,270 | $9.5M | $1.3M |
| Summary | ||||||||||
| Net change in cash | $16.0M | $38.6M | −$920,114 | −$12.1M | $3.6M | $3.5M | $6.3M | −$2.9M | $6.9M | $67,868 |
| Cash at end of period | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M | $16.7M | $13.2M | $6.9M | $9.8M | $2.9M |
| Free cash flow | −$12.2M | −$6.4M | −$7.9M | −$7.2M | −$7.3M | −$4.7M | −$3.0M | −$2.9M | −$2.6M | −$1.2M |
| Free cash flow margin | — | — | — | — | — | −3,809.0% | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 0.0% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$5.31B | −$3.9M | −$5.2M | −$3.4M | −$2.5M | −$2.6M | −$10.9M | −$1.3M | −$1.7M | −$1.6M | −$1.8M | −$2.0M |
| Depreciation & amortization | −$1.51B | — | — | — | — | — | — | — | — | — | $1.9M | — |
| Stock-based compensation | $1.43B | $1.7M | $1.1M | $1.1M | $1.3M | $1.4M | $278,612 | $199,122 | $334,390 | $328,661 | $474,206 | $474,138 |
| Change in working capital | −$213.8M | −$474,202 | $1.4M | $247,859 | −$22,900 | −$4.3M | $4.1M | $31,654 | −$295,879 | −$342,858 | −$206,190 | −$460,217 |
| Other non-cash items | $2.36B | −$799,634 | −$716,464 | $0 | $119,509 | −$119,509 | $4.6M | $0 | $0 | $0 | −$1.9M | $0 |
| Cash from operating activities | −$3.25B | −$3.5M | −$3.4M | −$2.1M | −$1.1M | −$5.7M | −$2.0M | −$1.1M | −$1.7M | −$1.7M | −$1.5M | −$1.9M |
| Investing activities | ||||||||||||
| Capital expenditures | −$4 | −$4 | $0 | −$2 | −$1 | −$4 | $0 | −$2 | −$2 | −$3 | −$1 | −$3 |
| Investments (net) | $4.1M | −$5.6M | −$62.2M | −$2.1M | $1.2M | −$325,828 | −$14.3M | $985,730 | −$2,423 | −$983,307 | $3.0M | −$13,052 |
| Acquisitions & other investing | $4.11B | $4 | $0 | $2 | $1 | $4 | $0 | $2 | $2 | $3 | $1 | $3 |
| Cash from investing activities | $4.12B | −$5.6M | −$62.2M | −$2.1M | $1.2M | −$325,828 | −$14.3M | $985,730 | −$2,423 | −$983,307 | $3.0M | −$13,052 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | $200,203 | −$200,203 | $0 | −$35.0M | — | — | — | −$16,534 | −$10 | −$11 | −$5 | −$8 |
| Shares issued | $0 | $0 | $0 | $127.8M | $0 | $0 | $56.2M | $0 | $0 | $3.2M | $339,870 | $254,910 |
| Other financing | −$647.6M | $0 | −$384,680 | −$381,349 | −$316,845 | −$115,682 | −$66,946 | $0 | −$9,909 | −$10,727 | −$5,317 | −$8,199 |
| Cash from financing activities | −$647.4M | −$200,203 | −$384,680 | $92.4M | −$316,845 | −$115,682 | $56.1M | −$16,534 | −$9,919 | $3.2M | $334,548 | $246,703 |
| Summary | ||||||||||||
| Net change in cash | $213.5M | −$9.3M | −$65.8M | $88.2M | −$209,473 | −$6.1M | $39.8M | −$99,847 | −$1.7M | $541,499 | $1.8M | −$1.7M |
| Cash at end of period | $52.76B | $52.5M | $61.8M | $127.7M | $39.5M | $39.7M | $45.8M | $6.0M | $6.1M | $7.8M | $7.3M | $5.5M |
| Free cash flow | −$3.25B | −$3.5M | −$3.4M | −$2.1M | −$1.1M | −$5.7M | −$2.0M | −$1.1M | −$1.7M | −$1.7M | −$1.5M | −$1.9M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
MNPR cash generation
In fiscal 2025 (ended December 31, 2025), Monopar Therapeutics generated -$12.2 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$12.2 million. It returned $35.0 million to shareholders through dividends ($0) and net share buybacks ($35.0 million). Cash and equivalents rose by $16.0 million over the year.
Related: MNPR income statement, MNPR balance sheet. See the MNPR stock overview for the latest quote and news.
MNPR cash flow FAQ
What is Monopar Therapeutics's free cash flow?
Monopar Therapeutics's free cash flow was -$12.2 million in fiscal 2025: -$12.2 million of operating cash flow minus $0 of capital expenditures It was -$6.4 million a year earlier..
How much cash does Monopar Therapeutics generate from operations?
Monopar Therapeutics generated -$12.2 million of cash from operating activities in fiscal 2025.
How much stock does Monopar Therapeutics buy back?
Monopar Therapeutics spent $35.0 million on net share repurchases in fiscal 2025.